Husain M, et al. - Via conducting an event-driven, randomized, double-blind, placebo-controlled trial involving 3,183 patients with type 2 diabetes at high cardiovascular risk, researchers assessed the cardiovascular outcomes associated with once-daily oral semaglutide, and aimed to establish cardiovascular safety of new therapies for type 2 diabetes. Patients were randomized to receive oral semaglutide or placebo. Gastrointestinal adverse events resulting discontinuation of oral semaglutide or placebo were more common with the former. Overall, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo in patients with type 2 diabetes.